Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 1 completed trials

    Completion Rate
    100%(1/1)
    Active Trials
    1(33%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 1
    2
    67%
    Phase 2
    1
    33%

    Phase Distribution

    2

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1Safety & dosage
    2(66.7%)
    Phase 2Efficacy & side effects
    1(33.3%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    1 of 1 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(1)
    Completed(1)
    Other(1)

    Detailed Status

    Suspended1
    Completed1
    Recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    1
    Success Rate
    100.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 12 (66.7%)
    Phase 21 (33.3%)

    Trials by Status

    suspended133%
    completed133%
    recruiting133%

    Recent Activity

    1 active trials
    Showing 3 of 3
    recruitingphase_2

    A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

    NCT06514794
    suspendedphase_1

    Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

    NCT05377827
    completedphase_1

    A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

    NCT04984356

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT06514794Phase 2

    A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

    Recruiting
    NCT05377827Phase 1

    Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

    Suspended
    NCT04984356Phase 1

    A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    3